The rise in outsourcing is a positive development for the research antibodies and reagents market. By outsourcing the development and production of antibodies and reagents, companies can reduce costs, increase efficiency, access expertise, and increase flexibility, thus creating opportunities in the research antibodies and reagents market. Also, an increasing number of local players in emerging markets, such as China, India, and Mexico, are offering their research antibodies and reagents products at lower prices than established market players. As a result, the pricing pressure on established players has increased, who are being compelled to adopt competitive pricing strategies to maintain their market shares and this is challenging market growth.
The report Research Antibodies & Reagents Market are projected to reach USD 16.2 billion by 2028 from USD 11.8 billion in 2023, at a CAGR of 6.5% during the forecast period.
Download PDF Brochure: –
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793
Key Market Dynamics:
Growth Drivers
- Increasing research activity and funding for R&D
- Growing industry-academia collaboration
Growth Opportunities
- Emerging markets
- Personalized medicine and protein therapeutics
- Growth in stem cell and neurobiology research
- Increasing focus on biomarker discovery
- Rising interest in outsourcing
Challenges
- Cost and time-intensive antibody development processes
- Pricing pressure faced by prominent market players.
Trends
- Increasing research on therapeutic antibodies
- Recombinant antibodies supporting the smooth transition from in vitro to in vivo
- Growing consolidation of the life sciences market for antibodies and reagents
Market Segmentation: –
On the basis of the product, the research antibodies and reagents market are segmented into reagents and antibodies. The antibodies segment is expected to grow at highest CAGR in forecast periods (2023-2028). Antibodies are essential for routine procedures, such as western blotting, flow cytometry, IHC, and ELISA.
On the basis of form, the research-use antibodies are categorized into monoclonal, polyclonal, and recombinant antibodies. The monoclonal antibodies segment accounted for the largest share of the research antibodies market by form in 2022.
On the Basis of type, the research reagents market are segmented into media &sera, stains & dyes, fixatives, buffers, solvents, enzymes, probes, and other reagents. In 2022, the media & sera reagent segment held the largest share of the global research reagents market.
On the basis of technology, the research antibodies and reagents market are segmented into ELISA, flow cytometry, western blotting, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. In 2022, the Enzyme-linked Immunosorbent Assay (ELISA) segment accounted for the largest share of the market.
On the basis of application, the research antibodies and reagents market are segmented into proteomics, drug development and Genomics. In 2022, the proteomics segment accounted for the largest share.
On the basis of end user, the research antibodies and reagents market are segmented into the pharmaceutical & biotechnology companies, research labortories, and Contract Research Organizations. The research laboratories segment accounted for the largest share of the market in 2022.
Regional Analysis:
The European market is expected to have the second largest market share in 2022. The growth of the overall market in Europe is attributed to an increase in R&D activities, rising government funding for drug discovery research, and increasing growth in the pharmaceutical & biological industries. In Europe, proteomics and genomics research for cancer and neurobiological diseases have increased in the last decade. between universities that are designed to promote excellence in research and education.
Recent Developments of Research Antibodies & Reagents Industry
- In August 2023, Danaher (US) entered into a definitive agreement to acquire all the outstanding shares of Abcam plc (UK). Through this development, Abcam is expected to operate as a standalone operating company within Danaher’s Life Sciences segment.
- In August 2023, Agilent Technologies, Inc. (US) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia. The facility is focused on building local capabilities to accelerate research and development (R&D) in life science research.
- In June 2023, Cell Signaling Technology, Inc. (US) and Lunaphore Technologies SA (Switzerland) have decided to partner to integrate CST antibodies into Lunaphore’s COMET platform for Spatial Biology research.
Request For Sample Pages: – https://www.marketsandmarkets.com/requestsampleNew.asp?id=94212793
Top Key Players: –
The prominent market players are Abcam plc (UK), Cell Signaling Technology, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), BD (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Danaher (US), Lonza (Switzerland), GenScript (China), and Revvity (US).
Related News:
